NCI may need to invest at least $125 million in new money in the Research Project Grant pool in 2018 if the institute plans on keeping the success rates for R01s comparable to 2017, said NCI Director Ned Sharpless.
What a difference a week makes.
A group of tobacco control advocates, one of whom receives money from Philip Morris International, issued a press release trumpeting that “E-Cigarettes are Saving Lives,” and attributed this conclusion to a recent report by the National Academy of Sciences, Engineering, and Medicine.
A policy now in the works at the Centers for Medicare and Medicaid Services will define settings where Medicare will pay for next generation sequencing.
Gary Reedy has a big turnaround project on his hands.
The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.
Marsha Fountain, retired president of The Oncology Group, died Jan. 7 after a long struggle with metastatic breast cancer. She was 65.
Roche has teamed up with the precision medicine company Syapse to develop software for measuring health outcomes and economic impact of precision medicine.
The American Society of Clinical Oncology has reached a deal that will allow two companies—Tempus and Precision Health AI—to curate and license the data in CancerLinQ, the professional society's venture into Big Data.
In his first talk to NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute's agenda and research portfolio.
